Drugs / Gene-modified CD34+ cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06506461 | Mar 2025 → Dec 2029 expected | sickle cell disease | St. Jude Children's Research Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gene-modified CD34+ cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06506461 ↗ |
| Modality | Cell therapy | “autologous infusion of clustered regularly interspaced palindromic repeats (CRISPR)/ CRISPR associated protein (Cas9)-edited CD34+ hematopoietic stem and progenitor cells (HSPCs)” NCT06506461 ↗ |
| Route | Intravenous | “Given Intravenous (IV)” NCT06506461 ↗ |